{"id":22085,"date":"2012-04-13T11:00:35","date_gmt":"2012-04-13T15:00:35","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=22085"},"modified":"2012-04-13T07:12:10","modified_gmt":"2012-04-13T11:12:10","slug":"22085","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2012\/04\/13\/22085\/","title":{"rendered":"it just didn’t work…"},"content":{"rendered":"
\n
\n
Early detection and intervention evaluation for peopleat risk of psychosis: multisite randomised controlled trial.<\/font><\/strong><\/u><\/a>
by Morrison AP, French P, Stewart SL, Birchwood M, Fowler D, Gumley AI, Jones PB, Bentall RP, Lewis SW, Murray GK, Patterson P, Brunet K, Conroy J, Parker S, Reilly T, Byrne R, Davies LM, Dunn G.<\/sup>
British Medical Journal<\/font><\/strong>. 2012 Apr 5;344
[full text on-line<\/font><\/u><\/a><\/strong>]<\/div>\n

<\/font><\/strong><\/p>\n

OBJECTIVE<\/font><\/strong>: To determine whether cognitive therapy is effective in preventing the worsening of emerging psychotic symptoms experienced by help seeking young people deemed to be at risk for serious conditions such as schizophrenia.
DESIGN<\/font><\/u><\/strong>: Multisite single blind randomised controlled trial.
SETTING<\/font><\/strong><\/u>: Diverse services at five UK sites.
PARTICIPANTS<\/font><\/strong><\/u>: 288 participants aged 14-35 years (mean 20.74, SD 4.34 years) at high riskof psychosis: 144 were assigned to cognitive therapy plus monitoring of mental state and 144 to monitoring of mental state only. Participants were followed-up for a minimum of 12 months and a maximum of 24 months.
INTERVENTION<\/font><\/strong><\/u>: Cognitive therapy (up to 26 (mean 9.1) sessions over six months) plus monitoring of mental state compared with monitoring of mental state only.
MAIN OUTCOME MEASURES<\/font><\/strong><\/u>: Primary outcome was scores on the comprehensive assessment of at risk mental states (CAARMS), which provides a dichotomous transition to psychosis score and ordinal scores for severity of psychotic symptoms and distress. Secondary outcomes included emotional dysfunction and quality of life.
RESULTS<\/font><\/strong><\/u>: Transition to psychosis based on intention to treat was analysed using discrete time survival models. Overall, the prevalence of transition was lower than expected (23\/288; 8%), with no significant difference between the two groups (proportional odds ratio 0.73, 95% confidence interval 0.32 to 1.68). Changes in severity of symptoms and distress, as well as secondary outcomes, were analysed using random effects regression (analysis of covariance) adjusted for site and baseline symptoms. Distress from psychotic symptoms did not differ (estimated difference at 12 months -3.00, 95% confidence interval -6.95 to 0.94) but their severity was significantly reduced in the group assigned to cognitive therapy (estimated between group effect size at 12 months -3.67, -6.71 to -0.64, P=0.018).
CONCLUSIONS<\/font><\/strong><\/u>: Cognitive therapy plus monitoring did not significantly reduce transition to psychosis or symptom related distress but reduced the severity of psychotic symptoms in young people at high risk. Most participants in both groups improved over time. The results have important implications for the at risk mental state concept.<\/sup><\/div>\n
<\/div>\n<\/blockquote>\n
Well, the same thing happened in Manchester England that happened in Australia. The preliminary studies [2. when n=a few<\/em>…<\/font><\/a><\/strong><\/u>] looked good, but when they tried to take it to Broadway, it just didn’t work. There’s only one conclusion to be reached unfortunately. We don’t know how to identify people who are going to become Schizophrenic in advance, at least not well enough to count. And treatment with the cognitive therapies tried so far doesn’t help. That’s too bad. Any dent would’ve been a welcome finding. This study, instead, simply confirms the Australian finding:<\/div>\n
\n
Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis.<\/font><\/strong><\/u><\/a>
by Yung AR, Phillips LJ, Nelson B, Francey SM, PanYuen H, Simmons MB, Ross ML, Kelly D, Baker K, Amminger GP, Berger G, Thompson AD, Thampi A, and McGorry PD.<\/sup>
Journal of Clinical Psychiatry<\/font><\/strong>. 2011 72(4):430-40.<\/div>\n

<\/p>\n

OBJECTIVE<\/font><\/strong><\/u>: Cognitive therapy and\/or low-dose antipsychotic administered during the prodromal phase of schizophrenia may prevent or delay the onset of full-blown illness. However, it is unclear which of these treatments are most effective, how long treatment should be given, and whether effects will be sustained over a prolonged period.<\/sup> <\/div>\n
METHOD<\/font><\/strong><\/u>: In order to examine these issues, we conducted a randomized controlled trial of cognitive therapy + risperidone; cognitive therapy + placebo; and supportive therapy + placebo in young people at ultra high risk for developing a psychotic disorder (that is, putatively prodromal). The main outcome was transition to psychotic disorder, with level of symptoms and functioning the secondary outcomes. This article reports the interim 6-month follow-up results. The study was conducted from August 2000 to May 2007.<\/sup><\/div>\n
RESULTS<\/font><\/strong><\/u>: Of a possible 464 eligible ultra high risk individuals, 115 were recruited to the randomized controlled trial (cognitive therapy + risperidone, n = 43; cognitive therapy + placebo, n = 44; and supportive therapy + placebo, n = 28). An additional 78 individuals agreed to follow-up assessments but not to randomization ("monitoring group," n = 78). At 6 months, 8 of the 115 participants (7.0%) and 4 of the monitoring group (5.1%) had developed psychotic disorder. There were no significant differences between the 3 randomized groups (log rank test, P = .92) or between all 4 groups (log rank test, P = .93). There was also no difference between the 4 groups in secondary measures, with all groups showing a reduction in symptoms and increased functioning.<\/sup> <\/div>\n
CONCLUSIONS<\/font><\/strong><\/u>: Rates of transition to psychosis were lower than expected, particularly in the control supportive therapy + placebo group. This may have accounted for the negative finding, as the sample was therefore underpowered to find any difference between groups. Alternatively, it may be that all treatments were equally effective or equally ineffective at 6 months.<\/sup><\/div>\n<\/blockquote>\n
I’m sorry it didn’t work. Schizophrenia can be a show-stopping disease and any prevention would’ve been good to see. Recruitment for this study ended almost three years ago. It’s hard for me to believe that the DSM-5 Task Force hasn’t known this was coming for a while and yet they’ve persisted in holding on to the Attenuated Psychosis Syndrome diagnosis. Now, Drs. McGorry, Yung, and the Manchester group oppose its inclusion:<\/div>\n
\n
"In summary, it is important that future research examines the developmental processes involved in both transition to psychosis and resilience within populations in an at risk mental state, but it seems highly premature to introduce a diagnostic category into DSM-V on the basis of risk of psychosis, given the low transition rate and high potential for natural recovery."<\/sup><\/div>\n<\/blockquote>\n
While it’s difficult for me to imagine that the DSM-5 Task Force will keep the Attenuated Psychosis Syndrome diagnostic category, they’ve shown little willingness to alter their course so far. At this point, trying to move forward with either removing the Bereavement Exclusion or the addition of the Attenuated Psychosis Syndrome would be destructive to the profession. They are in a bind of their own creation, and this publication offers them a way out of it. It also offers them a chance to self-destruct…<\/div>\n","protected":false},"excerpt":{"rendered":"

Early detection and intervention evaluation for peopleat risk of psychosis: multisite randomised controlled trial. by Morrison AP, French P, Stewart SL, Birchwood M, Fowler D, Gumley AI, Jones PB, Bentall RP, Lewis SW, Murray GK, Patterson P, Brunet K, Conroy J, Parker S, Reilly T, Byrne R, Davies LM, Dunn G. British Medical Journal. 2012 […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-22085","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/22085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=22085"}],"version-history":[{"count":19,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/22085\/revisions"}],"predecessor-version":[{"id":22089,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/22085\/revisions\/22089"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=22085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=22085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=22085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}